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ABSTRACT
Objectives: The aim of this study was to compare the efficacy of different HIV drug resistance
test reports (genotype and virtual phenotype) in patients who were changing their
antiretroviral therapy (ART).
Design: Randomised, open-label trial with 48-week followup.
Setting: The study was conducted in a network of primary healthcare sites in Australia and
New Zealand.
Participants: Patients failing current ART with plasma HIV RNA . 2000 copies/mL who
wished to change their current ART were eligible. Subjects were required to be . 18 years of
age, previously treated with ART, have no intercurrent illnesses requiring active therapy, and to
have provided written informed consent.
Interventions: Eligible subjects were randomly assigned to receive a genotype (group A) or
genotype plus virtual phenotype (group B) prior to selection of their new antiretroviral
regimen.
Outcome Measures: Patient groups were compared for patterns of ART selection and
surrogate outcomes (plasma viral load and CD4 counts) on an intention-to-treat basis over a
48-week period.
Results: Three hundred and twenty seven patients completing . one month of followup were
included in these analyses. Resistance tests were the primary means by which ART regimens
were selected (group A: 64%, group B: 62%; p ¼ 0.32). At 48 weeks, there were no significant
differences between the groups for mean change from baseline plasma HIV RNA (group A: 0.68
log copies/mL, group B: 0.58 log copies/mL; p ¼ 0.23) and mean change from baseline CD4þ
cell count (group A: 37 cells/mm
3, group B: 50 cells/mm
3; p ¼ 0.28).
Conclusions: In the absence of clear demonstrated benefits arising from the use of the virtual
phenotype interpretation, this study suggests resistance testing using genotyping linked to a
reliable interpretive algorithm is adequate for the management of HIV infection.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
HIV drug resistance was ﬁrst described three years after the
introduction of zidovudine for treatment of HIV infection
[1]. Resistance has subsequently been described for each
licensed antiretroviral therapy (ART). Some mutations caus-
ing resistance to one drug are known to confer cross-
resistance to others within the same class [2–4]. The develop-
ment of resistance to ART signiﬁcantly reduces drug efﬁcacy
and is an important cause of treatment failure.
HIV drug resistance testing is a recommended component
of several international ART treatment guidelines [5,6]. Three
different methodologies are currently used to evaluate ART
susceptibility in clinical HIV isolates; genotype, phenotype,
and virtual phenotype. In addition to the different analytical
techniques, myriad platforms for the interpretation of
laboratory data are available. Genotype testing involves the
sequencing of viral genes and the interpretation of mutations
detected in the gene sequence. Phenotypic testing directly
measures the susceptibility of a clinical HIV isolate to
antiretroviral drugs. The virtual phenotype predicts ART
susceptibility on the basis of mapping deﬁned point
mutations against an extensive database comprising virus
gene sequences with deﬁned phenotypic susceptibility to
antiretroviral drugs [7].
None of the current methods for resistance testing is ideal.
Genotypic testing may not correlate completely with pheno-
type, requires expert interpretation, and relies heavily on the
availability of unvalidated, rules-based algorithms. The
technique requires a minimum plasma HIV-1 viral load of
approximately 1,000 RNA copies/mL. Phenotypic testing is
slow and only available in highly specialised laboratories.
Moreover, the relationship between phenotypic inhibitory
concentrations (IC50, IC90) and virologic response under
continuing drug pressure (the so-called cutoff) requires
constant adjustment as more laboratory and clinical infor-
mation becomes available. Both types of resistance testing
may fail to detect minor quasi-species that may have clinical
signiﬁcance. Quality control of genotypic testing for se-
quence quality, the ability to detect nucleotide mixtures, the
interpretation of sequences obtained, and clinician familiar-
ity with the report generated, so that informed treatment
choices are made, remain issues of concern.
In general, both genotypic and phenotypic resistance
testing has been shown to provide virologic beneﬁt (reduction
in viral load and increased proportion of patients with HIV
viralloadbelow thelimitsofdetection) comparedwithcontrol
arms [8–11]. Clinicians have been encouraged to incorporate
resistance testing as part of their routine clinical assessment of
patients prior to initiating and/or changing therapy [12].
There is preliminary evidence that there are costs/beneﬁts
arising from the use of resistance testing [13,14]. More
recently, in a meta-analysis of published trials, the clinical
effectiveness of HIV resistance testing was questioned [15].
While phenotypic and virtual phenotypic testing have been
compared [16,17], the relative utilities of virtual phenotypic
and genotypic testing have not been assessed. The CREST
(can resistance testing enhance selection of therapy) Study
was designed as a randomized, prospective evaluation of
antiretroviral prescribing and surrogate marker outcome
following provision of resistance tests using a genotype alone
or a genotype plus virtual phenotype. The study also
supported a national quality assurance program for genotype
testing (that incorporated a unifying interpretative algo-
rithm) and the development of clinician familiarity with HIV-
1 resistance testing at a time when such testing was not
routinely available in Australia or New Zealand.
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Editorial Commentary
Background: Antiretroviral drugs are used to treat patients with HIV
infection, with good evidence that they improve prognosis. However,
mutations develop in the HIV genome that allow it to evade successful
treatment—known as drug resistance—and such mutations are known
against every class of antiretroviral drug. Resistance can cause treatment
failure and limit the treatment options available. Different types of tests
are often used to detect resistance and to work out whether patients
should switch to a different drug regimen. Currently, the different types
of tests include genotype testing (direct sequencing of genes from virus
samples infecting a patient); phenotype testing (a test that assesses the
sensitivity of a patient’s HIV sample to different drugs), and virtual
phenotype testing (a way of interpreting genotype data that estimates
the likely viral response to different drugs). The researchers of this study
did a trial to find out whether providing an additional virtual phenotype
report would be beneficial to patients, as compared with a genotype
report alone. The main outcome was HIV viral load after 12 months of
treatment, but the researchers also looked at differences in drug
regimens prescribed, number of treatment changes in the study, and
changes in CD4þ (the type of white blood cell infected by HIV) counts.
What this trial shows: The researchers found that the main endpoint of
the trial (HIV viral load after 12 months) was no different in patients
whose clinicians had received a virtual phenotype report as well as a
genotype report, compared with those who had received a genotype
report alone. In addition, the average number of drugs prescribed was
no different between patients in the two different arms of the trial, and
there was no difference in number of drug regimen changes, and no
change in immune response (measured using CD4þcell levels). However,
more drugs predicted to be sensitive were prescribed by clinicians who
got both a genotype and virtual phenotype report, as compared with
clinicians who received only the genotype report.
Strengths and limitations: The size of the trial (338 patients recruited)
was large enough to properly test the hypothesis that providing a virtual
phenotype report as well as a genotype report would result in lower HIV
viral loads. Randomization of patients to either intervention ensured that
the comparison groups were well-balanced, and the researchers also
tested whether selection bias had affected the results (i.e., testing for the
possibility that clinicians could predict which intervention participants
would receive, and change recruitment into the trial as a result). They
found no evidence for selection bias occurring within the trial. However,
interpreting the results is difficult because the trial did not directly
compare the two different testing platforms, but rather looked at
whether providing a virtual phenotype report as well as a genotype
report was better than providing a genotype report alone. The
investigators also acknowledge that since the trial was conducted, the
cutoffs for interpreting genotype information as resistant have been
lowered. The findings may therefore not translate precisely to the
current situation.
Contribution to the evidence: Other cohort studies and clinical trials
have shown that patients offered resistance testing respond better to
antiretroviral therapy compared with those who were not, but the
clinical effectiveness of different resistance testing methods is not
known. This study provides additional data on the respective benefits of
genotype testing versus genotype plus provision of virtual phenotype.
Another trial comparing genotype versus virtual phenotype has also
found that the different interpretation methods perform similarly.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.METHODS
Participants
HIV-infected patients taking combination ART, with plasma
HIV RNA viral load . 2000 copies/mL, who were willing to
change therapy and who were more than 18 years of age were
eligible to enter the study. Patients were ineligible if they
were ART naive, experiencing an acute illness warranting
therapeutic management, or judged by the investigator as
being unable to understand or comply with the protocol. All
patients were required to give written, informed consent
prior to entering the study. Institutional ethics approval was
granted for all sites involved in the study. Subjects were
recruited from a network comprising 41 clinical sites
(hospitals, sexual health clinics, and primary care facilities)
in Australia and New Zealand.
Interventions
Patients were randomly assigned to receive a genotypic
resistance test (group A) or a genotypic resistance test plus a
virtual phenotype (group B).
Resistance Testing
Each clinical site selected one laboratory to undertake
genotype testing for their study participants.
Genotype Testing
Blood was collected from eligible patients into tubes contain-
ing ACD or EDTA anticoagulant at the randomisation visit
and sent to the designated laboratory for genotyping of HIV
reverse transcriptase (RT) and protease (PR) genes. The
laboratories used a variety of platforms to generate the HIV
genotype; TRUGENE HIV-1 assay (Visible Genetics, Ontario,
Canada), n ¼ 1; ViroSeq HIV-1 Genotyping System Version 2
(Applied Biosystems, Foster City, California, United States), n
¼ 2; six laboratories used in-house assays with primers that
enabled ampliﬁcation and sequencing of the PR and RT genes.
All laboratories participated in an ongoing quality assurance
program to ensure that the differing technologies yielded
consistent results [18,19]. Genotype results were reported
using a trial speciﬁc, rules-based algorithm (Table 1) and a
common report format. The report identiﬁed a given isolate
as being sensitive, intermediate, or resistant to a given ART.
Virtual Phenotype
The viral RT and PR sequences generated for patients in
group B were sent electronically to Virco (Mechelen,
Belgium) for generation of a virtual phenotype report. When
there were insufﬁcient matches in the database, a Virco rules-
based interpretation of the sequence was made. At the time
the study was performed, the VircoGEN II platform employed
arbitrary clinical cutoffs for each class of ART (,4-fold, 4–10-
fold and .10-fold changes for NNRTIs, PIs, and NRTIs,
respectively). VircoGEN II was the only format of virtual
phenotype used for the duration of the study.
Objectives
Our primary hypothesis was that provision of the virtual
phenotype report would result in signiﬁcant clinical beneﬁt
relative to provision of an HIV genotype report alone in
terms of changes in plasma HIV RNA over 48 weeks.
We were also interested in patterns of antiretroviral
selection and use following receipt of the study resistance
test results, changes in CD4þ cell count, and any associations
between clinical outcome and a range of baseline factors.
Outcomes
The primary endpoint was mean change in log plasma HIV–
RNA load between the baseline measurement and that
obtained 48 weeks later. Secondary endpoints were: the
differences between the planned medication and the regimen
selected at baseline following provision of the resistance test
result; the proportion of patients with undetectable (,400
copies/mL) plasma HIV-RNA load at 48 weeks; the time
weighted average change in log plasma HIV–RNA load from
baseline; the number of ART treatment changes over
duration of study; the change in CD4þ cell count from
baseline to 48 weeks; the time-weighted average change in
CD4þ cell count from baseline and time to ﬁrst ART change.
Sample Size
Based on an estimate of variability in mean change in log
plasma HIV-RNA load between baseline and 48 weeks,
corresponding to a standard deviation of 1.0 log10, 300
patients were required to detect a difference between groups
of 0.35 log10 with 80% power using a two-sided signiﬁcance
level of 5%.
Randomization
Randomization was performed using a central telephone
randomization ofﬁce located at NCHECR. The random-
ization was stratiﬁed by site, ﬁrst or subsequent combination
antiretroviral treatment change, and baseline plasma HIV-
RNA load (,/.10,000 copies/mL). Computer-generated
stratiﬁed randomization lists were generated using a blocking
factor of two. The block size was known only to key staff at the
coordinating centre. It was not known by any of the sites.
Eligible patients were randomised in equal proportions to
receive either an HIV genotype report (group A) or both an
HIV genotype report and a virtual phenotype report
(VircoGen II—group B).
Investigators recorded the ARV regimen they would next
prescribe based on their clinical judgment prior to receiving
the resistance report. Demographic, CD4þ cell count, HIV
RNA load, CDC classiﬁcation, ART history, and ART
intolerance data were also collected at baseline.
Treatment Failure on Study
Patients who failed treatment on the study (deﬁned as plasma
HIV RNA load . 5,000 copies/mL on two occasions more than
two weeks apart after having achieved ,400 copies/mL while
on the study) could receive an additional HIV resistance test
consistent with their original randomisation.
Statistical Methods
Primary treatment comparisons were performed using a
modiﬁed intention to treat (MITT) approach, using all
randomised patients with baseline and at least one followup
visit. Continuous endpoints were analysed using nonpara-
metric rank-sum tests; binary variables using Fisher’s Exact
tests. Time to event endpoints were analysed using survival
analysis methods. Secondary treatment comparisons were
also performed using a strict intention to treat (SITT)
approach, including all patients without data as failures,
joint worst outcomes, or events at time zero, as appropriate.
SITT p-values are presented in addition to MITT results.
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The CREST StudyTwo prespeciﬁed subgroup analyses were performed—
according to number of previous antiretroviral combinations
received ( 7 versus 8þ combinations), and by number of
drugs resistant according to genotype ( 6 versus 7þresistant
drugs). Evidence for subgroup effects were formally assessed
by testing for statistically signiﬁcant interactions between
subgroup and randomized treatment group. At the request of
the journal, we also performed one further subgroup analysis
according to whether patients were the ﬁrst or second
randomized within each randomization block [20]. The aim
of this analysis was to try to assess whether the small block size
of two adopted in this trial may have led to biased patient
allocation, which might be detectable as differing treatment
effects according to whether a patient was the ﬁrst or second
randomized in each block.
Resistance Testing
Baseline resistance proﬁles were analysed according to
randomisation group using the genotype results only. Addi-
tionally, a formal comparison of genotype interpretation
according to the Crest Algorithm (Table 1) and virtual
phenotype (using locally derived sequence data analysed by
VircoGen II) was undertaken on group B patients. Resistance
proﬁles were summarised according to the total number of
ART to which a patient’s virus was classiﬁed as resistant, of
intermediate resistance, or sensitive, and the proportion of
patients whose virus was resistant to all available ART.
The results of resistance testing for each ART were cross-
tabulated against the genotype or virtual phenotype. The
proportion of genotype or virtual phenotype results that
were derived from a rules-based assessment was calculated.
The number of drugs against which the virus was classiﬁed as
sensitive or intermediate by genotype but resistant by virtual
phenotype and vice versa was assessed. A score of the overall
difference between genotype and virtual phenotype was then
calculated.
RESULTS
Patient Disposition, Recruitment, and Baseline
Characteristics
A total of 338 patients were randomised into the study
between October 2001 and April 2002. Eleven (3.3%) did not
have any followup data and were excluded from all analyses.
The remaining 327 patients composed the intent-to treat
population. Twenty-ﬁve patients (7.6%) were lost to followup
before 48 weeks, 12 from group A and 13 from group B.
These patients were included in analyses using their available
data. For participant disposition, please refer to Figure 1. We
did not record the numbers of patients screened for the trial
who were ineligible.
Baseline patient characteristics were summarised accord-
ing to randomisation group and are shown in Table 2. The
groups were well matched for all AIDS/demographic varia-
bles, including gender, prior AIDS, and risk factor. Patients in
group A were statistically signiﬁcantly older than in group B,
but the mean difference of two years is not considered
clinically relevant. Median plasma HIV RNA at baseline was
16,750 copies/mL in group A and 16,300 copies/mL in group
B. Baseline mean CD4þcell count was 290 cells/mm
3 in group
A and 318 cells/mm
3 in group B. All patients had previously
received nucleoside RT inhibitors (NRTIs), 80% of group A
and 79% of group B, had previously received a non-
nucleoside RT inhibitor (NNRTI), and 90% in both groups
had previously received a protease inhibitor (PI). The mean
total number of ARV drugs ever received was eight and the
mean duration of ARV treatment was six years in both
groups. The mean number of combinations of ARVs used was
.......................................................................................................................................................................................
Table 1. Rules-Based Algorithm for Determining Genotypic Susceptibility to PI, NNRTI, and NRTI in the CREST Substudy
Class Drug Primary Resistance Mutations Secondary Resistance Mutations
PI Amprenavir I50V or I84V
Indinavir No single mutation identified, M46I and V82A/F/T
predisposes to resistance to indinavir
Lopinavir I84V
Nelfinavir D30N or L90M
Ritonavir V82A/F or I84V
Aaquinavir G48V or L90M
All PIs At least two of D30N, M46I, I50V, V82A/F/T, I84V, or L90M
NNRTI Delavirdine K103N and/or Y181C and/or P236L K103T
Efavirenz K103N and/or Y188L and/or G190S L100I or V108I or Y181C or P225H
Nevirapine K103N and/or V106A and/or V108I and/or Y181C/I
and/or Y188C and/or G190A
A98G or L100I
NRTI Abacavir M184V with K65R or L74V or Y115F K65R or L74V or M184V or M41L or D67N
or K70R or T215F/Y or K219Q
Didanosine K65R or L74V M184V
Lamivudine M184V M184I
E44A/D and/or V118I with T215Y and/or M41L
Stavudine V75T M41L and/or D67N and/or K70R and/or
T215F/Y and/or K219Q
Zalcitabine K65R or T69D or L74V or V75T M184V
Zidovudine M41L and/or D67N and/or K70R and/or T215F/Y and/or K219Q
NRTIs 68SS69 with T215Y
MDR NRTIs T69S plus SS or SA or SG with or without T215F/Y
DDI/DDC/ZDV Q151M with A62V and/or V75I and/or F77L and/or F116Y
MDR, mutations conferring multidrug resistance to NRTIs.
DOI: 10.1371/journal.pctr.0010018.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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The CREST Studyeight for group A and seven for group B. On average, patients
in both treatment groups were known to be intolerant to one
ARV drug. The median turnaround times for generation of
resistance reports were 33 days (range 16–118 days) for group
A and 33 days (range 7–127 days) for group B.
Outcomes and Estimation
After 48 weeks there were no signiﬁcant differences between
the groups for mean change from baseline plasma HIV RNA
(group A ¼  0.68 log copies/mL, group B ¼  0.58 log copies/
mL: MITT p ¼ 0.230, SITT p ¼ 0.685) (Figure 2). The time-
weighted mean viral log change from baseline was  0.61 in
group A and 0.58 for those in group B (MITT p¼0.876, SITT
p ¼ 0.952).
A total of 67 patients (46%) in group A and 60 (42%) in
group B had undetectable viral loads at week 48 (MITT p ¼
0.553, SITT p ¼ 0.502). Mean change from baseline CD4þ cell
count at 48 weeks was not signiﬁcantly different between
study groups (group Aþ37 cells/mm
3, group Bþ50 cells/mm
3;
MITT p ¼ 0.275, SITT p ¼ 0.296). The mean CD4þ weighted
change from baseline at week 48 was þ24 cells/mm
3 in group
A patients and þ39 cells/mm
3 in group B (MITT p ¼ 0.401,
SITT p¼0.221). Nine (5.5%) patients in group A and seven in
group B (4.3%) experienced an AIDS-deﬁning illness during
the study. The time to developing an AIDS deﬁning illness
was not signiﬁcantly different between the arms (MITT p ¼
0.625, SITT p ¼ 0.579). Eight patients died during the study,
six from group A and two from group B.
We performed two prespeciﬁed subgroup analyses, in
which we examined our study endpoints in patients with or
without extensive prior treatment histories, and with multi-
ple drug resistance point mutations or not. We did not
observe any evidence of beneﬁt for either resistance test
platform in any of these analyses (unpublished data). The
analysis according to randomization order also did not reveal
any evidence of treatment effects. In patients randomized
ﬁrst within each block, mean log viral load decreases at 48
weeks were  0.70 logs (SD ¼ 1.14) and  0.62 (SD ¼ 0.97) in
genotype and virtual phenotype patients, respectively (p ¼
0.574). In patients randomized second, the mean log
Figure 1. Participant Disposition
DOI: 10.1371/journal.pctr.0010018.g001
.......................................................................................
Table 2. Summary of Patient Baseline Characteristics accord-
ing to Genotype and Genotype Plus Virtual Phenotype
Characteristic Genotype
Alone,
Group A,
(n ¼ 164)
Genotype þ
Virtual
Phenotype,
Group B,
(n ¼ 163)
p-Value
Male 159 155 0.414
Caucasian 156 148 0.136
Homosexual transmission 149 145 0.587
Prior AIDS 57 59 0.818
Mean age (years) 43 41 0.027
Median plasma HIV RNA
(copies/mL)
16,750 16,300 0.748
Mean CD4þ cell count
(cells/mm
3)
290 318 0.990
Median number prior of ARVs 8 8 0.377
Median duration of HIV t
reatment (years)
5.9 5.6 0.975
Median number of ARV regimens 8 7 0.272
DOI: 10.1371/journal.pctr.0010018.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Comparison of Virological Response by Study Arm
DOI: 10.1371/journal.pctr.0010018.g002
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The CREST Studydecreases were  0.65 (SD ¼ 0.94) and  0.51 (SD ¼ 1.09),
respectively, (p ¼ 0.144). There was no statistical evidence of
an interaction between treatment group and randomization
order (p ¼ 0.535).
Ancillary Analyses
ARV prescribing at baseline. The average number of ARVs in
regimens prior to randomisation was three in both groups.
The mean duration of the current ARV regimen was 18
months in group A and 20 months in group B. The ARV drug
class prescribed at study entry prior to resistance testing is
shown in Table 3. Three patients (1.9%) in group A, and none
in group B, had evidence of genotypic resistance across all
drug classes.
Data summarised in Table 4 indicate that the virtual
phenotype reported signiﬁcantly more sensitive ARVs than
the genotype platform (MITT and SITT p , 0.001).
Furthermore, on average clinicians prescribed signiﬁcantly
more sensitive drugs to patients in arm B than in arm A
(MITT and SITT and p ,0.001). There were no apparent
differences between study groups for discrepancies between
the planned and actual regimen employed. This is despite
clear evidence that the overwhelming majority of patients in
both groups started a regimen of therapy different from the
one planned following receipt and interpretation of either
resistance test result.
The planned ARV regimen was compared with the
prescribed ARV regimen following resistance testing. The
mean number of ARVs planned and then prescribed in both
study groups was three (MITT p ¼ 0.311, SITT p ¼ 0.342).
Thirty two patients (19%) in group A and 22 (14%) in group
B were actually prescribed the ARV regimen that had been
planned based on best clinical judgment (MITT p ¼ 0.180,
SITT p ¼ 0.182). The reasons cited as being most important
for selection of the prescribed ARV regimen were: resistance
test result (group A, 64%; group B, 62%; MITT p ¼ 0.732,
SITT p ¼ 0.824), and ARV history (group A: 32%; group B:
28%; MITT p¼0.631, SITT p¼0.634). The median number of
ARV drugs against which plasma virus was sensitive was six in
group A and eight in group B. The median number of drugs
prescribed against which the virus was sensitive in the
resistance test was one in group A and two in group B.
ARV changes during the study. The mean number of
changes to prescribed ARV drugs for any reason was three in
group A patients and 2.7 in group B (MITT p¼0.702, SITT p¼
0.649). Neither the time to ﬁrst ARV change nor time to
treatment failure were signiﬁcantly different between the
groups (MITT p ¼ 0.882, SITT p ¼ 0.829, and MITT p ¼ 0.382,
SITT p¼0.557, respectively). The number of protocol-deﬁned
treatment failures was 11 (6.7%) in group A and 16 (9.8%) in
group B.
Resistance results. Concordance between the results from
genotyping and virtual phenotyping for each drug class were
determined (Figures 3–5). There was a signiﬁcant difference
between the susceptibility reported for all NRTIs, with
genotype results classifying more patients as harbouring
resistant virus than virtual phenotype (p-values   0.002 for all
drug classes). NNRTI susceptibility was reported with greater
concordance, and only delavirdine resistance was reported
more often by genotype than virtual phenotype (p ¼ 0.02).
There was no signiﬁcant difference in test concordance for
indinavir and nelﬁnavir, but genotype results reported
signiﬁcantly more clinical isolates resistant to saquinavir (p
¼,0.001) and amprenavir (p¼,0.001) and virtual phenotype
reported signiﬁcantly more resistance to ritonavir (p¼0.001).
DISCUSSION
Interpretation
The CREST study was designed to identify whether there was
any beneﬁt in providing a virtual phenotype report in
addition to a rules-based genotype to assist in the selection
of ARV therapy. A no-resistance test control arm was not
used because at the time of conducting the trial neither
investigators nor patient advocate groups felt there was
sufﬁcient clinical equipoise for a control group. Approx-
imately 40% of study patients had viral loads below the level
.......................................................................................
Table 3. Summary of the ARV Drug Classes Used at
Enrollment
ARV Drug Class Genotype
Alone,
Group A,
n ¼ 164
(Percent)
Genotype þ
Virtual
Phenotype,
Group B,
n ¼ 163
(Percent)
p-Value
No current ARV 1 (0.6) 0 0.999
NRTIs only 10 (6) 15 (9) 0.307
PIs only 2 (1) 0 0.498
NRTIs þ NNRTIs 66 (35) 67 (41) 0.911
NRTIs þ PIs 56 (41) 54 (33) 0.907
NNRTIs þ PIs 1 (0.6) 2 (1) 0.623
NRTIs þ NNRTIs þ PIs 28 (17) 25 (15) 0.764
DOI: 10.1371/journal.pctr.0010018.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 4. Selected Resistance Test Data and Prescribing Practice Information
ARV Prescribing Information Arm A
(n ¼ 164)
Arm B
(n ¼ 163)
MITT
p-Value
SITT
p-Value
Mean number of drugs
a Sensitive 5.5 8.1 ,0.001 ,0.001
Intermediate 2.6 1.6 ns ns
Resistant 5.9 4.2 ns ns
Mean number of sensitive drugs
a prescribed 1.4 2.1 ,0.001 ,0.001
Percent discordance between planned and actual regimen 81 86 0.297 0.299
a Results are for VircoGEN II in Arm B.
ns, Not significant.
DOI: 10.1371/journal.pctr.0010018.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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The CREST Studyof detection at week 48. Previous studies have also shown the
beneﬁt of resistance data when selecting a new ARV regimen
[8–11]. The choice of which test to use remains a decision for
individual clinicians, who may be inﬂuenced by factors such
as the test method offered, conﬁdence in the quality of
performance of complex laboratory testing procedures, cost,
turnaround time, and ease of interpretation of the test report
provided.
In this heavily pretreated group of patients, we found no
virological or immunological differences at week 48 between
these two resistance test platforms.
Subsequent to this study, the clinical cutoffs for resistance
employed by virtual phenotyping were lowered from .10-
fold to 2.0, 2.0, and 1.8 for didanosine, zalcitabine, and
stavudine, respectively. As such it is tempting to dismiss the
relevance of the ﬁndings. We would argue that the impact of
the new cutoffs would be to reduce the number of drugs that
are reported back to clinicians as being sensitive and in so
doing further reduce the apparent differences between the
two virtual phenotype and the genotypic test platforms. This
view cannot be informed by data from our trial because the
necessary analyses are not possible.
Generalizability
It is reasonably well-established that extensive prior use of
ART results in multidrug resistant virus and that the utility of
drug resistance testing in heavily pretreated patients is
Figure 3. Comparison of Genotype and Virtual Phenotype Reports for NRTIs
DOI: 10.1371/journal.pctr.0010018.g003
Figure 4. Comparison of Genotype and Virtual Phenotype Reports for PIs
DOI: 10.1371/journal.pctr.0010018.g004
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The CREST Studyquestionable because their options are very limited [6,10].
However, we found no evidence to suggest that the two test
platforms provided any clear beneﬁt in the predeﬁned
patient strata with more or less than eight prior regimens
and those with virus with resistance to more or less than six
available drugs. This observation is supported by ﬁndings
from the MuSa Study [21].
Our randomised comparison provided clinicians with
either one or two forms of report and interpretation
describing the scale and scope of antiretroviral drug
resistance in clinical isolates taken from patients in the trial.
It is not possible to ascertain with conﬁdence which report
carried more weight when clinicians reviewed the results
provided for patients in group B. Consequently there may be
concern that many decisions regarding future treatment in
that group were made on the basis of interpretations
provided by the genotype result alone. However, our data
clearly show that virtual phenotype results provided clini-
cians and their patients with signiﬁcantly more treatment
options and this resulted in signiﬁcantly more apparently
active drugs being prescribed for patients enrolled in group
B. As such, we contend that for the most part our randomised
comparison maintained integrity and that the results should
be viewed as valid and robust comparisons. Of some
importance in this regard is the fact that it is not possible
to exclude an interpretation of genotype from the virtual
phenotype report since the observed point mutations for a
given sample are an integral part of that report.
A majority of clinical HIV isolates in each study arm had at
least one ARV with either intermediate or full sensitivity.
However, clinician prescribing was limited as not all of these
ARVs could be used. For example, a viable combination
regimen could not be constructed from three NNRTI drugs.
A further limitation of this study is that the impact of low
dose ritonavir, used to inhibit cytochrome P450 isoenzymes
and thereby increase the plasma levels of co-administered PIs,
was not examined. Further work is needed to interpret
resistance results when a boosted PI regimen is planned
[22,23]. Ongoing reﬁnement and modiﬁcation of the test
platforms does impact upon the generalizability of these
results.
CREST resulted in all Australian and New Zealand HIV
reference laboratories being able to offer HIV genotype
testing and participation in a local quality assurance
program. Other outcomes were sharing of expertise, collab-
oration between different laboratories, and the availability of
a standardised genotypic interpretation and reporting for-
mat developed and maintained by Australian experts. The
study was undertaken in a wide variety of settings and
provided investigators with access to HIV resistance test
reports. The genotype report was designed to be user friendly
for both those experienced and inexperienced in interpret-
ing the results. The provision of a resistance test result
signiﬁcantly impacted the choice of ARVs prescribed across
all sites, both in general practice and in specialist hospitals.
Overall Evidence
Overall, CREST found that HIV resistance test results
affected ARV prescribing but there was no additional beneﬁt
derived from receiving a virtual phenotype report in addition
to a genotype report. This may be due to factors including the
quality of the genotype interpretation developed for CREST
and the high biological cutoff used in the virtual phenotype
analysis. Similar data have been generated in one other trial
[21]. Across a range of studies conducted in a diverse patient
population there is little data to indicate that any of the
myriad interpretation methods offer reliable and predictable
beneﬁts. The choice of test platform should probably there-
fore reﬂect factors such as availability, cost, and familiarity.
Figure 5. Comparison of Genotype and Virtual Phenotype Reports for NNRTIs
DOI: 10.1371/journal.pctr.0010018.g005
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SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010018.sd001 (56 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010018.sd002 (1.0 MB DOC).
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